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Background: Pregnant women with mild gestational hyperglycemia present a high risk for hypertension and obesity,
and appear to reproduce the model of metabolic syndrome in pregnancy, including hyperinsulinemia and insulin
resistance. Diabetic patients have a higher frequency of the IRS-1 Gly972Arg variant and this polymorphism is directly
related to insulin resistance and subsequent hyperglycemia. In diabetes, hyperglycemia and other associated factors
generate reactive oxygen species that increase DNA damage. The aims of this study were to evaluate the presence of
the IRS-1 Arg972 polymorphism in pregnant women with diabetes or mild gestational hyperglycemia, and in their
newborns. Additionally, we evaluated the level of primary DNA damage in lymphocytes of Brazilian pregnant women
and the relationship between the amount of genetic damage and presence of the polymorphism.
Methods: A based on the oral glucose tolerance test (OGTT) results and on glycemic profiles (GP), as follows: non-
diabetic group, mild gestational hyperglycemia (MGH) and diabetic group. Eighty-five newborns were included in the
study. Maternal peripheral blood samples and umbilical cord blood samples (5–10 mL) were collected for genotyping
by PCR-RFLP and for comet assays.
Results: The prevalence of genotype Gly/Arg in pregnant women groups was not statistically significant. In newborns,
the frequency of Gly/Arg was significantly higher in the MGH and diabetic groups than in the non-diabetic group.
Taken together, groups IIA and IIB (IIA + IIB; diabetes) presented lower amounts of DNA damage than the non-diabetic
group (p = 0.064). No significant association was detected between genetic damage and the presence of the Arg972
genotype in pregnant women.
Conclusion: The polymorphism was more prevalent in newborns of diabetic and MGH women. We believe that it is
necessary to increase the number of subjects to be examined in order to better determine the biological role of the
Arg972 polymorphism in these patients. Despite being classified as low-risk, pregnant women with mild gestational
hyperglycemia characterize a population of maternal and perinatal adverse outcomes, and that, together with their
newborns, require better monitoring by professionals and health services.
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Maternal hyperglycemia in pregnancy is associated with
adverse outcomes, including birth weight ≥90th percent-
ile, delivery by cesarean section, neonatal hypoglycemia,
and fetal hyperinsulinemia [1]. These associations occur
across the full range of increased maternal glucose
levels, including those below that classified as overt dia-
betes [1]. In fact, our previous findings have shown that
not only gestational diabetes mellitus (GDM), but also
mild gestational hyperglycemia (MGH) is responsible for
adverse perinatal outcomes (APO), such as high inci-
dence of macrosomia, perinatal mortality, hypoglycemia,
hyperbilirubinemia, prematurity, and congenital anomal-
ies [2]. MGH is a risk factor for metabolic syndrome
(MS) in pregnancy. Patients with MGH have hypergly-
cemia, hyperinsulinemia, and insulin resistance that per-
sists at 6 weeks postpartum [3]. After 10 to 12 years of
the index-pregnancy, type 2 Diabetes Mellitus (DM2)
was confirmed in 16.7% of MGH pregnant women [4].
Approximately one-third of the variation in fasting glu-
cose in healthy non-diabetic and non-pregnant women is
genetic [5]. Insulin directly regulates peripheral glucose
uptake in muscle and adipose tissue [6]. The insulin path-
way is mediated by a complex and highly integrated net-
work that controls various processes. Considering the
importance of insulin receptor substrate (IRS), especially
IRS-1 on the insulin pathway, genetic alterations, such as
polymorphisms, can alter the operation of this pathway.
Common genetic variants at multiple loci are robustly as-
sociated with fasting glucose [7], DM2, and related gly-
cemic traits [8,9]. Porzio et al. [10] described different
frequencies of the insulin receptor substrate gene (IRS-1)
polymorphisms between healthy (5%) and DM2 (10%–
20%) subjects. IRS-1 is a highly polymorphic gene, located
at 2q36, and its Gly972Arg variant is usually found in
DM2 patients, especially in those who have insulin resist-
ance, suggesting an important role of this polymorphism
in the pathogenesis of diabetes [10]. The IRS-1 Gly972Arg
variant is also associated with GDM. Tok et al. evaluated
the polymorphism in 62 GDM women, and 14.5% pre-
sented this variant. Those patients with this gene poly-
morphism are obese in early pregnancy, and have high
levels of glucose and fasting serum insulin [11]. Recently,
we observed a higher frequency of the IRS-1 972Arg
polymorphism in DM2 and GDM pregnant women,
and also a direct link between this gene variant and
obesity and insulin resistance [12]. Although several au-
thors have demonstrated a relationship between the
Gly972Arg polymorphism and diabetes, Vergotine et al.
[13] showed that the Gly972Arg polymorphism was not
associated with obesity, insulin resistance/sensitivity, or
DM2 in the South African population.
The literature has also reported that diabetes hypergly-
cemia is related to increased DNA damage [14]. In fact,diabetes and hyperglycemia can generate reactive oxygen
species (ROS) that may induce genetic damage. Some
studies have shown increased DNA damage in leuko-
cytes of type 1 and type 2 Diabetes Mellitus individuals
[15], Pitozzi et al., [16] have previously described that
patients with DM2 have a higher frequency of cells with
DNA damage than those with DM1. Recently, Zengi
et al., [17] also showed increased oxidative DNA damage
in lean normoglycemic offspring of DM2 patients.
Diabetic patients have a higher frequency of the IRS-1
Gly972Arg variant and this polymorphism is directly re-
lated to insulin resistance and subsequent hypergly-
cemia. In diabetes, hyperglycemia and other associated
factors generate reactive oxygen species that increase
DNA damage. Since GDM and MHG pregnant women
share some characteristics and induce similar effects in
the offspring, we investigated if diabetic (DM2 even be-
fore pregnancy), gestational diabetic, and MGH pregnant
women with the IRS-1 972Arg variant, might have
higher levels of DNA damage. Therefore, the objectives
of this study were to evaluate the presence of the IRS-1
Arg972 polymorphism in diabetic and mild gestational
hyperglycemic pregnant women, and in their newborns.
We evaluated the level of primary DNA damage in lym-
phocytes in these pregnant women. Additionally, we
evaluated the relationship between the amount of gen-
etic damage and the presence of the polymorphism.
The presence of the polymorphism in women with
MGH and diabetes was relatively more common, al-
though there was no statistically significant difference.
Possibly due to insulin treatment, diet and exercises in
MGH and diabetic groups and the non-diabetic group is
at high risk for gestational diabetes mellitus, the DNA




The study protocol was approved by the Research Ethics
Committee of Botucatu Medical School number (OF
545/2004) and all participants provided written informed
consent.
The investigation was undertaken at the Diabetes and
Pregnancy Tertiary Center, at the Botucatu Medical
School, UNESP, Brazil. Eligible pregnant women under-
went positive screening for GDM, including fasting gly-
cemia level ≥90 mg/dL and risk factors for GDM in the
late second trimester, according to the Brazilian Health
Ministry recommendations, followed by referral for a
diagnostic oral standard 75-g glucose tolerance test
(OGTT) and a glycemic profile between the 24th and
28th weeks. GDM was confirmed when an abnormal
screening test was followed by two or more values on a
standard 75-g OGTT using the Carpenter and Coustan
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screening was followed by normal values of OGTT and
the altered glycemic profile was characterized by fasting
glycemia higher than 90 mg/dl and/or postprandial gly-
cemia higher than 130 mg/dl [2,19]. Pregnant women with
DM2 came to the service with a prior diagnosis. Inclusion
criteria were as follows: classified in the study groups, ges-
tational age of entry into the treatment protocol of 30
weeks for MGH and 20 weeks for type 2 DM, prenatal
care and birth on the service, and consent form signature.
DM1 patients were not included in this study. Exclusion
criteria were multiple pregnancies, fetal malformations,
congenital malformations, and gestational age at delivery
lower than 34 weeks.
A total of 226 pregnant women were stratified into the
following three groups: non-diabetic group, normal
OGTT and glycemic profile (n = 62); mild gestational
hyperglycemia, normal OGTT and abnormal glycemic
profile (n = 63); and diabetic, abnormal OGTT and gly-
cemic profile (n = 101). A total of 85 newborns were
also evaluated: 31 newborns of mothers with normal glu-
cose tolerance (non-diabetic group), and 12 from MGH
and 42 from diabetic mothers.
For maternal hyperglycemia regulation, pregnant MGH
and GDM women were treated with diet, physical exer-
cise, and insulin therapy (if necessary) after the diagnosis,
and women with type 2 diabetes were treated since before
the beginning of pregnancy [20,21].
Anthropometric and biochemical analyses
The body mass index (BMI) was calculated by body
weight divided by the square of height. Plasma glucose
was measured using the glucose oxidase method (Glucose
Analyzer II Beckman®, Fullerton, California, USA). Gly-
cated hemoglobin (HbA1c) was analyzed by HPLC (high-
performance liquid chromatography; D10TM Hemoglobin
Testing System, BIO RAD® laboratories, Hercules, CA,
USA). The glycemic mean was calculated by the arith-
metic mean of plasma glucose measured in all glycemic
profiles performed at diagnosis. Large for gestational age
(LGA) was defined as neonatal birth weight ≥ 90th per-
centile for gestational age (the weight/gestational age), and
sex was determined according to service protocol.
Gene polymorphism and DNA damage
From week 34 of gestation and before the onset of labor,
maternal blood samples (5–10 mL) were collected into
tubes with EDTA (Vacutainer®). From newborns, a blood
sample (5 mL) was collected from the umbilical cord vein,
also into tubes with EDTA (Vacutainer®). For gene poly-
morphism assays, a blood aliquot was stored at −20°C for
subsequent DNA extraction, according to Salazar et al.
[22]. The extracted DNA was maintained at −20°C until
gene amplification by PCR. The concentration of DNAwas measured in a spectrophotometer, and the integrity
was determined by direct agarose gel electrophoresis. The
Gly972Arg genotype was verified by the PCR-restriction
fragment length polymorphism (RFLP) technique. A 263-
base pair (bp) fragment containing the Gly972Arg seg-
ment was amplified with primers described by Almind
et al. [23]: IRSF (5′ CTTCTGTCAGGTGTCCATCC 3′)
and IRSR (5′ TGGCGAGGTGTCCACGTAGC 3′). The
amplified fragment was confirmed by 6% polyacrylamide
gel electrophoresis stained with silver nitrate. After con-
firmation of amplification, 263-bp PCR products were
digested with 3 U of BstNI (New England Biolabs, Ips-
wich, MA, USA). The products of enzymatic digestion
were analyzed by 6% polyacrylamide gel electrophoresis
stained with silver nitrate and using a DNA molecular size
marker. The fragments had the following sizes: 159, 81,
and 23 bp in Gly972 homozygotes; 159, 108, 81, 51, and
23 bp in Gly/Arg972 heterozygotes; and 108, 81, 51, and
23 bp in Arg972 homozygotes.
The comet assay was used to evaluate primary DNA
damage. Blood lymphocytes were isolated by Ficoll® gradi-
ent, and the assay was performed as in [24]. The lympho-
cytes (20 μl) were mixed with low melting point (LMP)
agarose (120 μl), placed on pre-coated slides with normal
melting point (NMP) agarose, and immediately covered
with coverslip. The slides were left at 4°C for 10 min to so-
lidify the agarose. The coverslip was gently removed and
slides were immersed into an ice-cold freshly prepared lysis
solution (2.5 M NaCl, 100 mM EDTA, 10 mM Tris, with
1% Triton 100-X, and 10% dimethyl sulfoxide). As a posi-
tive control, lymphocytes from healthy individuals were
treated in vitro with H2O2 (200 μM), and incubated
on ice for 30 min according to the protocol described
by Blasiak et al. [25]. After lysis, the slides were placed
onto a horizontal electrophoresis unit filled with fresh
electrophoresis alkaline buffer (300 mM NaOH and 1 mM
EDTA, pH >13). The alkali unwinding duration was 20
min. Electrophoresis was conducted at 4°C for 30 min at 25
V/cm and 300 mA. All the steps were carried out under
minimal illumination. The slides were neutralized in a buf-
fer (0.4 M Tris at pH 7.5) and fixed with absolute alcohol.
The slides were stained with ethidium bromide (20 μg/ml
in distilled H2O; 50 μl/slide), and analyzed in a fluorescence
microscope connected to a charge-coupled device (CCD)
camera and a personal computer-based analysis system
(Comet Assay IV, Perceptive Instruments, UK) in order to
determine the extent of DNA damage. Tail intensity (% of
migrated DNA in the tail) was used do express DNA dam-
age. One hundred randomly selected cells (50 from each of
two replicate slides) were scored per blood sample.
Statistical analysis
Analysis of variance (ANOVA), followed by Tukey’s mul-
tiple comparison test, was used for analyzing the
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and newborn). The Chi-square test was used to compare
the frequencies of genotypes between the groups (preg-
nant women and newborns) and also for newborn
weight classification. A two-factor interaction model was
used in the associations. For DNA damage among the
experimental groups, Gamma distribution was applied
because the data presented non-normal distribution. Lo-
gistic regression was applied in the association between
DNA damage and genotype. The level of statistical sig-
nificance adopted was p < 0.05.
Results
Table 1 shows the characteristics of the pregnant women
(age, glycemic mean, initial and final BMI, and HbA1c)
and newborns (plasma glucose and weight classification).
For pregnant women, age, and initial and final BMI did
not differ between the groups. MGH and diabetic groups
showed higher glycemic means compared with the non-
diabetic group (p > 0.05). Additionally, the glycemic
mean was higher in the diabetic group than in the MGH
group (p < 0.05). Diabetic pregnant women presented
higher HbA1c when compared to those from the non-
diabetic and MGH groups (p < 0.05). In newborns,
plasma glucose concentrations were not different be-
tween the groups (p > 0.05). Regarding weight, the
MGH group presented a lower frequency of newbornsTable 1 Characteristics of study population
Pregnant women
Non-diabetic
Number of subjects 62
Age (years) 29.70 ± 5.50
Glycemic Mean (mg/dL) 80.56 ± 8.76
Initial BMI (Kg/m2) 29.34 ± 8.39
Final BMI (Kg/m2) 33.82 ± 8.01
HbA1c 5.45 ± 0.53
Non-diabetic
Number of subjects 31





MGH: Mild gestational hyperglycemia.
BMI: Body Mass Index, HbA1C: Glycated Hemoglobin, SGA: small for gestational age
AGA: adequate for gestational age, LGA: large for gestational age.
Data presented as mean ± standard deviation.
*p < 0.05 – statistically significant compared to non-diabetic group (Tukey’s multipl
#p < 0.05 – statistically significant compared to MGH group (Tukey’s multiple comp
αp < 0.05 – statistically significant compared to newborns of non-diabetic group (Ch
βp < 0.05 – statistically significant compared to newborns of diabetic group (Chi-sqwith adequate body weight for gestational age (AGA)
than the non-diabetic and diabetic groups (p < 0.05).
LGA newborns were more frequent in the MGH and
diabetic groups than in the non-diabetic group (p <
0.05), and were more frequent in the MGH group than
the diabetic group (p < 0.05).
The prevalence of the Gly/Arg heterozygote genotype
was 12.90% (8/62), 19.5% (12/63), and 14.85% (15/101)
in women from the non-diabetic, MGH, and diabetic
groups, respectively. No statistically significant differ-
ences between the groups were detected (p = 0.61;
Table 2). Only one pregnant woman from the non-
diabetic group was homozygous for the Gly972Arg poly-
morphism. In newborns, the frequency of Gly/Arg was
significantly (p < 0.05) higher in the MGH (16.67%) and
diabetic groups (23.81%) than in the non-diabetic group
(0.0%) (Table 2). Genotype distribution in both pregnant
women and newborns was according to Hardy–Wein-
berg equilibrium.
Table 3 shows the amount of DNA damage (tail inten-
sity) in pregnant women. A lower level of damage was
observed in the diabetic group compared to the non-
diabetic group (p < 0.05). Table 4 shows the association
between tail intensity and the Arg972 genotype in preg-
nant women, highlighting the genotype and the groups.
The logistic regression showed no significant association
(p > 0.05).MGH Diabetic
63 101
31.50 ± 4.20 31.30 ± 5.40
97.69 ± 7.85* 108.50 ± 15.82*#
31.93 ± 9.43 32.49 ± 8.29
36.17 ± 7.91 36.12 ± 6.62




66.73 ± 22.59 69.56 ± 31.84
00 (0.0%) 03 (7.3%)
8 (66.6%)αβ 34 (82.9%)










Gly/Gly 54 (87.10%) 51 (80.95%) 86 (85.15%)
Gly/Arg 08 (12.90%) 12 (19.05%) 15 (14.85%)
Allele Frequencya
“G” Allele 93.5% 90.4% 92.5%
“A” Allele 6.5% 9.6% 7.5%
Total 62 63 101
Newborns
Newborn of non-diabetic Newborn of MGH Newborn of diabetic
Genotype
Gly/Gly 31 (100.0%) 10 (83.33%) 32 (76.19%)
Gly/Arg 0 (0.0%) 2 (16.67%)* 10 (23.81%)*
Allele Frequencya
“G” Allele 100.0% 91.6% 88.1%
“A” Allele 0.0% 8.4% 11.9%
Total 31 12 42
MGH: Mild gestational hyperglycemia.
Data presented as N (%).
aData presented as %.
*p < 0.05 compared to non-diabetic group (Chi-square test).
Table 4 DNA damage (tail intensity) according to the IRS-
1 Arg972 considering pregnant women study groups
Groups Genotype Tail intensity mean ± SD
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The present study aimed to evaluate the presence of the
Arg972 polymorphism of the IRS-1 gene in diabetic
pregnant women or those with mild gestational hyper-
glycemia, as well as in their newborns, and to evaluate
and correlate with genotoxicity in these pregnant
women. Genotype frequencies did not differ significantly
between the groups of pregnant women, but the pres-
ence of the polymorphism was relatively more common
in women presenting mild gestational hyperglycemia
and diabetes (gestational and overt diabetes).
Orkunoglu et al. [26] found a similar frequency of poly-
morphisms in 186 Turkish individuals with BMI <25, i.e.,
12.90% in control subjects and 14.2% in type 2 diabetics.
Moreover, in a meta-analysis, it was concluded that 8.6%
of healthy subjects and 11.4% of patients with non-insulin
dependent diabetes mellitus (NIDDM) had this poly-
morphism with an odds ratio of 1.25 (95% CI 1.05–1.48)










38.81 ± 38.13 37.59 ± 36.28 36.19 ± 37.29*
MGH: Mild gestational hyperglycemia.
*p = 0.0064 compared to non-diabetic group (Gamma distribution).GDM and confirmed that this variant may define a sub-
group of patients who tended to be obese. This suggests
that it might be related to insulin resistance, which is seen
in obese patients with GDM. Falluca et al. [28] verified a
frequency of 11.0% of the polymorphism in women with
GDM, 9.8% in gestational impaired glucose tolerance (G-
IGT), and 7.9% in women with a negative glucose-
challenge test (NGT) result, suggesting that the IRS-1
genetic polymorphism is involved in the occurrence of
gestational diabetes, as well as type 2 diabetes mellitus.
After comparison of our findings with the literature data,
it was observed that the frequency of this polymorphism
is higher in our study population, although this was not
statistically different.Non-diabetic GG (n = 35) 38.6 ± 17.0
GA (n = 04) 36.06 ± 20.2
MGH GG (n = 21) 38.32 ± 13.5
GA (n = 03) 30.16 ± 11.6
Diabetic GG (n = 40) 34.7 ± 11.3
GA (n = 07) 43.3 ± 13.3
MGH: Mild gestational hyperglycemia.
No statistical difference (logistic regression).
Gelaleti et al. Diabetology & Metabolic Syndrome  (2015) 7:30 Page 6 of 8The mild gestational hyperglycemia pregnant women
presented the highest frequency of the polymorphism,
although without statistical difference. Negrato et al.
[29] demonstrated that patients with MGH showed
higher HOMA-IR (index for insulin resistance evalu-
ation) values and lower peripheral insulin sensitivity (al-
though this was not a statistically significant difference)
compared with the normal glucose tolerance group, sug-
gesting that besides presenting insulin resistance, they
may also have a compensatory hyperinsulinemia. There
is evidence of the relationship between the presence of
the polymorphism Arg972 and insulin resistance, where
the individuals with the polymorphism present low levels
of fasting glucose and C-peptide, as well as impaired in-
sulin synthesis and secretion in the presence of glucose
[23,30,31]. Shirakami et al. [32] showed that in obese
mice, IRS-1 knockout produces severe insulin resistance
and lower expression of insulin receptor substrate (IRS-
1 and IRS-2).
Regarding DNA damage, the comet assay was used to
evaluate basal DNA damage levels in pregnant women
with either diabetes or mild hyperglycemia. The DNA
damage levels were lower in the diabetic group com-
pared to the non-diabetic group. In the non-diabetic
group, who showed risk factors for gestational diabetes
mellitus, OGTT and GP indicated no hyperglycemia or
change in glucose metabolism. Major risk factors pre-
sented in this group included overweight and obesity,
which may be associated with a sedentary lifestyle and
an unbalanced diet. Availability of transport, devices de-
signed to facilitate daily activities, easy food access, and
the fact that high-fat and high-sugar foods are frequently
the cheapest, have created an “obesogenic” environment
[33], which may be one factor to explain the increased
levels of basal DNA damage observed here. Karbownik-
Lewinska et al. [34] showed that overweight and obesity
in adults are directly associated with increased oxidative
damage to macromolecules.
Pregnant women in the MGH and diabetic groups also
show the same risk factors as the non-diabetic group,
however, MGH and diabetic groups underwent medical
monitoring and treatment during pregnancy. The treat-
ments applied to these pregnant women included phys-
ical activity, diet, and insulin therapy as needed.
Pregnant women of the MGH and diabetic groups were
diagnosed between the 24th and 28th weeks of gestation,
and blood samples were collected from the 36th week,
and therefore, we have a minimum of 8 weeks of such
treatments. Due to the reduced need, only a small per-
centage of pregnant women with MGH were treated
with insulin during pregnancy, and this may be the rea-
son for basal DNA damage are not as lower as the preg-
nant women of diabetic group, which besides diet and
exercises, most were treated with insulin. Supportingthis hypothesis, Wayhs et al. [35] showed significant re-
ductions in the DNA damage index in diabetic animals
treated with insulin, suggesting that treatment with insu-
lin protects against oxidative DNA damage.
Wang and Huang (2005) [36] observed that moderate
exercise attenuates lymphocyte apoptosis induced by
oxidative stress, possibly by improving intracellular anti-
oxidative capacity. Kim et al. [37] showed that 9 weeks of
training with three types of exercise increased the activity
of antioxidant enzymes and consequently decreased the
lipoperoxidation, which was verified by reduced plasma
MDA concentration and lymphocyte DNA damage. Siu
et al. [38] also confirmed that 8 and 20 weeks of habitual
exercise conferred increased resistance of rat lympho-
cytes to oxidant-induced DNA damage. Diet and life-
style can also contribute to the reduction of DNA
damage. Staruchová et al. [39] suggested that a well-
balanced food consumption with higher fruit and vegeta-
bles intake has a protective effect against oxidative dam-
age. Ochi & Sakai [40] showing that oxidative stress can
be greatly reduced by the improvement of lifestyle, such
as diet. These facts show that despite these groups of
pregnant women presenting diabetes and mild gestational
hyperglycemia, the medical monitoring and treatment
they received during pregnancy contributed to the de-
creased levels of basal DNA damage.
In the present study, there was no association between
the presence of the Arg972 polymorphism of the IRS-1
gene and the basal DNA damage in these groups of
pregnant women. In addition to the presence of the
polymorphism not differing in the pregnant group, the
basal DNA damage level in the diabetic group was re-
duced compared with the non-diabetic group possibly
due to medical monitoring and treatment this group re-
ceived during pregnancy.
Although our newborn sample size is small, children of
the MGH and diabetic groups showed a higher prevalence
of the Arg972 polymorphism compared with children of
the non-diabetic group. Despite the polymorphism not
differing among the mothers, their newborns of MGH
and diabetic mothers presented a higher prevalence of
polymorphism. We did not find manuscripts discussing
the polymorphism frequency in newborns of diabetic
mothers to compare and discuss this data, but, Bezerra
et al., [41,42] shows a frequency of 12.9% of the Arg972
polymorphism in healthy newborns, confirming the higher
polymorphism frequency in newborns of MGH and dia-
betic mothers found in our manuscript. With the result of
the polymorphism evaluation in newborns, it is necessary
to monitor the development of these childrens more
closely and intervention preventively to control the nega-
tive effects that the presence of this polymorphism can
bring. Some studies have shown that the presence of the
Arg972 polymorphism in newborns is associated with
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cumference in neonates, reinforcing the hypothesis that
genetically determined insulin resistance and/or reduced
insulin secretion can result in impaired insulin-mediated
growth in the fetus [41,42]. There is a close relationship
between this polymorphism and DM2 [31], DMG [11,28],
obesity [43-45], and insulin resistance [12,23,31,32]. In
addition, newborns of the MGH and diabetic groups had
a higher frequency of large body weight for gestational
age. Rudge [46] showed that newborns of women with
MGH presented 53.8% for macrosomia, a proportion
similar to the 51.9% observed in gestational and overt dia-
betes. The perinatal mortality rate is 41‰, which is similar
to diabetic pregnant women and ten-fold higher than nor-
mal glucose tolerance pregnant women [21]. The attribut-
able risk of perinatal death in this group is 4.16%, which is
comparable to that identified in groups of diabetic preg-
nant women [47].
There was no statistical difference between the geno-
types of pregnant women. When the relationship be-
tween the polymorphism and basal DNA damage was
evaluated, it was not possible to establish an association.
The polymorphism was more prevalent in newborns of
diabetic and MGH women. We believe that it is neces-
sary to increase the number of subjects to be examined
in order to better determine the biological role of the
Arg972 polymorphism in these patients. Despite being
classified as low-risk, pregnant women with mild gesta-
tional hyperglycemia characterize a population of mater-
nal and perinatal adverse outcomes, and that, together
with their newborns, require better monitoring by pro-
fessionals and health services.
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